SEOUL – South Korea’s biosimilar frontrunner Celltrion Inc. received approval from the Ministry of Food and Drug Safety for sales in Korea of Herzuma (trastuzumab), a biosimilar of Roche’s blockbuster Herceptin (trastuzumab). MFDS approved the compound for early and advanced HER2-positive breast cancer and for advanced stomach cancer.
The product is Celltrion’s second approved monoclonal antibody biosimilar following Remsima, a biosimilar of Johnson & Johnson’s tumor necrosis...